At the time of exit, LSNE was a specialised pharmaceutical contract development and manufacturing organisation (CDMO) and a market leader in lyophilisation (freeze-drying) and aseptic fill and finish services for injectable drugs.

The company provided end-to-end development and manufacturing services for clinical trial materials and commercial volumes to biopharma customers. LSNE had six CGMP (current good manufacturing practices) facilities, four located in New Hampshire, one in Wisconsin and one in Leon, Spain.